Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Rick Bright Selected as New BARDA Director

by Global Biodefense Staff
November 15, 2016
Biomedical Advanced Research and Development Authority

Biomedical Advanced Research and Development AuthorityThe U.S. Department of Health and Human Services has announced the selection of Dr. Rick Bright as the new Deputy Assistant Secretary for Preparedness and Response, and Director of the Biomedical Advanced Research and Development Authority (BARDA).

Bright has been with BARDA since 2010.  Most recently, he served as Director of the BARDA’s Influenza and Emerging Infectious Diseases Division and he previously led the BARDA Influenza Division’s International Program.

Bright began his career in vaccine and therapeutics development at the Centers for Disease Control and Prevention, where he focused on avian and human influenza viruses, antiviral drugs and the development novel assays for high throughput surveillance for resistance to antiviral drugs.

Bright has also worked in the biotechnology industry where he served as the Director of Immunology at Altea Therapeutics and Vice President of Research and Development and Global Influenza Programs at Novavax, Inc.  Rounding out his experience in the public and private sectors, in 2008, Dr. Bright joined PATH as the Scientific Director of the Influenza Vaccine Project in the Vaccine Development Global Program and the Director of the Influenza Vaccine Capacity Building Project in Vietnam.

“BARDA succeeds through strong relationships with federal, private sector and non-governmental entities, and in vetting the candidates for the BARDA Director position we engaged subject matter experts and leaders from across ASPR and the PHEMCE,” noted Assistant Secretary Nicole Lurie. “In a strong field, Rick Bright stood out, with a clear vision for leading BARDA and collaborating with PHEMCE partners in a rapidly changing mission space.

Bright will continue and expand upon the work of his predecessor, Acting BARDA Director Dr. Richard Hatchett. In the past year under Hatchett, BARDA has responded to the emergence of Zika by jump-starting the development of vaccines, diagnostics and blood screening products, while continuing with CBRN and pandemic influenza program activities, and launching a new program in the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

Bright received his PhD in Immunology and Molecular Pathogenesis from Emory University (Atlanta, GA) and his BS in Biology (Medical Technology) and Physical Sciences from Auburn University (Montgomery, AL).

Dr. Bright assumes his new position as the Director of BARDA on November 13, 2016.

Tags: ASPRBARDAHHSLeadership

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC